 |
Enisoprost |
|---|---|
| Trade Name | |
| Orphan Indication | For use in organ transplant patients to diminish the nephrotoxicity induced by cyclosporine |
| USA Market Approval | USA |
| USA Designation Date | 1989-10-20 00:00:00 |
| Sponsor | G.D. Searle & Company;4901 Searle Parkway;Skokie, IL, 60077 |
